Taipei, Taiwan, July 21, 2016 --(PR.com
)-- Scientists and medical researchers have made efforts to combat the progression of Alzheimer’s disease using a number of different approaches, out of which two have become generally accepted: impeding the build-up of noxious protein aggregates known as tau tangles and averting β amyloid plaques from accumulating in the brain, both of which could cause the degeneration of the central nervous system and lead to dementia as a result.
Researchers at Braincure Biotech prefer the latter approach, considering that the loss of the G protein-coupled receptor 3 (abbreviated GPR3) could reduce the amyloid plaque accumulation and increase cognitive functions.
The team led by Sírnir Thorsson has presented the results of their research earlier this week:
“We have determined that the G protein-coupled receptor 3, a protein which also found in the brain, is responsible for the production of amyloid-beta peptides and the aggregation of amyloid plaques,” said Thorsson. “Our findings suggest that the lack of G protein-coupled receptor 3 relieves cognitive deterioration and mitigates amyloid pathology in various condition-relevant models. The research determined that the G protein-coupled receptor 3 is a prime target for Alzheimer’s disease therapy and offers an important level of confirmation which is essential for future efforts in discovering effective drugs to combat this condition.”
Their therapeutic target is supported by the fact that they have proven that when G protein-coupled receptor 3 production is increased it corresponds with the progression of the condition in postmortem brain tissue from two separate groups of Alzheimer’s disease patients.
Given the series of impediments that relate to the development of efficient Alzheimer’s disease treatments over the last decade, the results of this research represent a step forward towards expanding the general understanding of the condition and its causes.
About Braincure Biotech
Braincure Biotech is an innovative company specialized in biotechnology as well as biopharmaceuticals, committed to pursuing the development of original treatment procedures with the aim of combating dementias and an emphasis on Alzheimer’s disease. We possess one of the most extensive international pipelines for the treatment of Alzheimer’s and also a comprehensive strategy for product growth.
Address: Taipei Far Eastern Plaza, No. 207, Section 2, Dun Hua South Road, Taipei 106, Taiwan (R.O.C.).